CLDX Key Stats
|Revenue (Quarterly YoY Growth)||-68.52%|
|EPS Diluted (TTM)||-1.029|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-76.30M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-2361%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- Can Heart Drugs Disrupt an Emerging Breast Cancer Market? Fool Dec 4
- Pre-Open Stock Movers 12/04: (OCLS) (PLUG) (OMED) Higher; (AMBI) (EXPR) (OVTI) Lower (more...) Street Insider Dec 4
- After Hours Stock Movers 12/03: (CCXI) (GWRE) (JCP) Higher; (OVTI) (ACMP) (CLDX) Lower (more...) Street Insider Dec 3
- Celldex Therapeutics (CLDX) Announces 6.5M Common Secondary Offering Street Insider Dec 3
- Today's Post-Market Laggard Is Celldex Therapeutics (CLDX) The Street Dec 3
- Celldex Therapeutics' CEO Presents at 2013 Deutsche Bank BioFEST Conference (Transcript) Seeking Alpha Dec 2
- Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer noodls Dec 2
- Celldex Therapeutics (CLDX) Initiates METRIC Study Street Insider Dec 2
- Celldex Announces Upcoming Presentation at the Deutsche Bank 2013 BioFEST noodls Nov 27
- Celldex, ImmunoCellular Fall And Rise On Hype And Hope Seeking Alpha Nov 26
CLDX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Celldex Therapeutics is up 324.6% over the last year vs S&P 500 Total Return up 30.02%, ACADIA Pharmaceuticals up 374.4%, and Isis Pharmaceuticals up 318.8%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for CLDX
Pro Report PDF for CLDX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CLDX Pro Report PDF
Pro Strategies Featuring CLDX
Did Celldex Therapeutics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Celldex Therapeutics, Inc., is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.